Atlas Trials

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

Clinical trial NCT00914732 · COMPLETED

Trial details

NCT number
NCT00914732
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Smallpox
Start date
2010-02-01
Primary completion
2011-04-01
Enrollment
523

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.